198 related articles for article (PubMed ID: 32818453)
21. Ulcerative Colitis.
Sonnenberg E; Siegmund B
Digestion; 2016; 94(4):181-185. PubMed ID: 27931025
[TBL] [Abstract][Full Text] [Related]
22. Next-Generation Therapeutics for Inflammatory Bowel Disease.
Dulai PS; Sandborn WJ
Curr Gastroenterol Rep; 2016 Sep; 18(9):51. PubMed ID: 27461274
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
[TBL] [Abstract][Full Text] [Related]
24. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
25. Emerging Therapies for Inflammatory Bowel Disease.
Weisshof R; El Jurdi K; Zmeter N; Rubin DT
Adv Ther; 2018 Nov; 35(11):1746-1762. PubMed ID: 30374806
[TBL] [Abstract][Full Text] [Related]
26. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis.
Kuwabara S; Tanimura S; Matsumoto S; Nakamura H; Horita T
Ann Rheum Dis; 2020 Aug; 79(8):1125-1126. PubMed ID: 32213500
[No Abstract] [Full Text] [Related]
27. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
28. Anti-TNF treatment of ulcerative colitis associated with idiopathic thrombocytopenic purpura.
Mares WG; Gerver J; Masclee AA; Pierik M
Inflamm Bowel Dis; 2011 Mar; 17(3):864-5. PubMed ID: 20848499
[No Abstract] [Full Text] [Related]
29. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.
Danese S; D'Amico F; Bonovas S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2018 Sep; 24(10):2106-2112. PubMed ID: 29697791
[TBL] [Abstract][Full Text] [Related]
30. Ustekinumab for treating ulcerative colitis: an expert opinion.
Biancone L; Ardizzone S; Armuzzi A; Castiglione F; D'Incà R; Danese S; Daperno M; Gionchetti P; Rizzello F; Scribano ML; Vecchi M; Orlando A
Expert Opin Biol Ther; 2020 Nov; 20(11):1321-1329. PubMed ID: 32662683
[TBL] [Abstract][Full Text] [Related]
31. Therapies in ankylosing spondylitis-from clinical trials to clinical practice.
Tahir H
Rheumatology (Oxford); 2018 Aug; 57(suppl_6):vi23-vi28. PubMed ID: 30445480
[TBL] [Abstract][Full Text] [Related]
32. Tofacitinib in ulcerative colitis - In the era of precision medicine'.
Harindranath S; Singh A
Dig Liver Dis; 2024 May; 56(5):909-910. PubMed ID: 38310053
[No Abstract] [Full Text] [Related]
33. Therapeutics: Silencing psoriasis.
Crow JM
Nature; 2012 Dec; 492(7429):S58-9. PubMed ID: 23254974
[No Abstract] [Full Text] [Related]
34. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future.
Pugliese D; Felice C; Papa A; Gasbarrini A; Rapaccini GL; Guidi L; Armuzzi A
Expert Rev Clin Immunol; 2017 Mar; 13(3):223-233. PubMed ID: 27687496
[TBL] [Abstract][Full Text] [Related]
35. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
36. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
37. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
38. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
Gniadecki R; Bang B; Sand C
Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
[No Abstract] [Full Text] [Related]
39. Therapeutic development in psoriasis.
Sobell JM; Leonardi CL
Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S69-72. PubMed ID: 25268599
[TBL] [Abstract][Full Text] [Related]
40. [Golimumab Therapy in Ulcerative Colitis].
Moon W
Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
